-+ 0.00%
-+ 0.00%
-+ 0.00%

*Eikon Completed Enrollment of TeLuRide-005 Phase 2 Trial of EIK1001 in First-Line Treatment of Stage 4 Non-Small Cell Lung Cancer >EIKN

Dow Jones·03/30/2026 11:50:00

Please log in to view news